On June 11, the Central Epidemic Command Center (CECC) announced that it has purchased drugs for the combined use in monoclonal antibody therapy that can be used to treat COVID-19 patients with mild-to-moderate cases who are at risk of developing severe cases so as to reduce their risk of developing severe cases and requiring hospitalization and alleviate the medical care load for severe cases.